Biomapas, an integrated life sciences services provider, has acquired Pinnaxis, a Noida, India-based global pharmacovigilance technology and consulting company. The acquisition was reported on October 6, 2026, and the financial terms were not disclosed.
Pinnaxis specializes in safety system implementation and upgrades, data migration, system integration, validation, reporting and analytics, and managed services. The acquisition strengthens Biomapas’ drug safety technology capabilities by adding engineering and configuration expertise across major safety platforms, including Veeva Safety Vault, Oracle Argus, and ArisGlobal, as well as established relationships with safety database providers. Pinnaxis also adds more than 100 technical experts and proprietary tools and accelerators for safety data migration, reporting, and case intake automation.
Pinnaxis will lead Biomapas’ Consulting & Digital business unit, which will shape the company’s use of technology and innovation across its services, including greater adoption of automation and AI in routine safety work. The acquisition also expands Biomapas’ U.S. presence through Pinnaxis’ established client base and New Jersey office, supporting Biomapas’ plans to grow its North American business.
Xavier Duburcq, CEO of Biomapas, stated that Pinnaxis brings deep expertise in the technology behind drug safety, strengthening Biomapas' ability to connect specialist services with supporting systems. Nishant Rana, Founder & CEO of Pinnaxis, noted that joining Biomapas is a strategic move that allows Pinnaxis to reach clients across Europe and beyond and offer more than technology alone.